The Association Between Comorbidities and a High-Risk Status According to COPD GOLD Groups

Sertçelik, Ümran; Sertçelik, Ahmet; Huseynova, Khurshud; Alkan, Asli; Damadoglu, Ebru; Coplu, Lutfi

doi:10.32552/2022.ActaMedica.818

The Association Between Comorbidities and a High-Risk Status According to COPD GOLD Groups

Ümran Özden SERTÇELİK, (Ankara Şehir Hastanesi Göğüs Hastalıkları Kliniği, Ankara, Türkiye)

Ahmet SERTÇELİK, (Hacettepe Üniversitesi Tıp Fakültesi Anabilim Dalı Halk Sağlığı, Epidemiyoloji Anabilim Dalı, Ankara, türkiye)

Khurshud HUSEYNOVA, (HB Guven Clinic, Department of Chest Diseases, Baku, Azerbaijan.)

Aslı ÖNCEL, (Yenimahalle Eğitim ve Araştırma Hastanesi, Göğüs Hastalıkları Anabilim Dalı, Ankara, Türkiye.)

Ebru ÇELEBİOĞLU, (Hacettepe Üniversitesi Tıp Fakültesi Anabilim Dalı Göğüs Hastalıkları, Allerji ve Klinik Anabilim Dalı İmmünoloji, Ankara, Türkiye.)

Lütfi ÇÖPLÜ (Hacettepe Üniversitesi Tıp Fakültesi Anabilim Dalı Göğüs Hastalıkları Bölümü, Ankara, Türkiye.)

Acta Medica

8 2

Yıl: 2023 Cilt: 54 Sayı: 1 Sayfa Aralığı: 27 - 34 Metin Dili: İngilizce DOI: 10.32552/2022.ActaMedica.818 İndeks Tarihi: 30-05-2023

The Association Between Comorbidities and a High-Risk Status According to COPD GOLD Groups

Öz:

Objective: The natural course of the chronic obstructive pulmonary disease (COPD) is thought to be affected by the severity of COPD, frequency of episodes, as well as the presence of comorbid conditions. It was aimed to explore the effect of comorbid conditions on high-risk status in stable COPD patients. Material and methods: Study participants consisted of stable COPD patients attending to the pulmonology outpatient unit of a tertiary center between 15th May 2018 and 12th Dec 2019. Demographic data, comorbidities, clinical index scores, modified Charlson comorbidity index score (mCCI), BODE index score, and the Short Form 36 (SF-36) scores as a generic life quality measure were recorded. Global Initiative for Chronic Obstructive Lung Disease (GOLD) groups were determined based on symptoms and exacerbations. Results: There were 23(25.8%), 31(34.8%), 2(2.2%), and 33(37.1%) patients in GOLD gropus A, B, C, and D, respectively. Among these, A and B groups are considered as low-risk, and C and D groups are considered as high-risk. High risk patients had higher mCCI (p < 0.001) and were more likely to have hypertension (p=0.012), congestive cardiac failure (p=0.029), chronic renal failure (p=0.022), osteoporosis (p=0.001), and anemia (p<0.001). In a logistic regression analysis performed to examine the determinants of high-risk status in COPD-GOLD groups, biomass exposure was found to increase the likelihood of having a high riskstatus by 3-fold. Conclusion: Classification of stable COPD patients according to GOLD groups showed higher mCCI in subjects with high-risk status. Comorbidities and mCCI did not appear to affect the high-risk status. Biomass exposure was associated with an increased risk of having a high-risk status.

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

[1] Global strategy for diagnosis, management, and prevention of COPD. Global Initiative for Chronic Obstructive Lung Disease (GOLD). . Available from: http:// www.goldcopd.org/. Accessed June 5, 2022. . Published 2022. Accessed.
[2] Divo M, Cote C, de Torres JP, et al. Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012;186(2):155-161.
[3] Decramer M, Janssens W. Chronic obstructive pulmonary disease and comorbidities. Lancet Respir Med. 2013;1(1):73-83.
[4] Faner R, Cruz T, Lopez-Giraldo A, Agusti A. Network medicine, multimorbidity and the lung in the elderly. Eur Respir J. 2014;44(3):775-788.
[5] Fabbri LM, Rabe KF. From COPD to chronic systemic inflammatory syndrome? Lancet. 2007;370(9589):797-799.
[6] Miller J, Edwards LD, Agusti A, et al. Comorbidity, systemic inflammation and outcomes in the ECLIPSE cohort. Respir Med. 2013;107(9):1376-1384.
[7] Putcha N, Puhan MA, Hansel NN, Drummond MB, Boyd CM. Impact of co-morbidities on self-rated health in selfreported COPD: an analysis of NHANES 2001-2008. COPD. 2013;10(3):324-332.
[8] Body mass index-BMI. World Health Organisation Regional Office for Europe. https://www.euro.who.int/en/healthtopics/ disease-prevention/nutrition/a-healthy-lifestyle/ body-mass-index-bmi. Published 2022. Accessed2022.
[9] Ware JE, Jr., Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30(6):473-483.
[10] Pellegrino R, Viegi G, Brusasco V, et al. Interpretative strategies for lung function tests. Eur Respir J. 2005;26(5):948-968.
[11] Culver BH, Graham BL, Coates AL, et al. Recommendations for a Standardized Pulmonary Function Report. An Official American Thoracic Society Technical Statement. Am J Respir Crit Care Med. 2017;196(11):1463-1472.
[12] Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373-383.
[13] Beddhu S, Bruns FJ, Saul M, Seddon P, Zeidel ML. A simple comorbidity scale predicts clinical outcomes and costs in dialysis patients. Am J Med. 2000;108(8):609-613.
[14] Laboratories ATSCoPSfCPF. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002;166(1):111-117.
[15] Rehman AU, Shah S, Abbas G, et al. Assessment of risk factors responsible for rapid deterioration of lung function over a period of one year in patients with chronic obstructive pulmonary disease. Sci Rep. 2021;11(1):13578.
[16] Bikov A, Horvath A, Tomisa G, Bartfai L, Bartfai Z. Changes in the Burden of Comorbidities in Patients with COPD and Asthma-COPD Overlap According to the GOLD 2017 Recommendations. Lung. 2018;196(5):591-599.
[17] Hanlon P, Nicholl BI, Jani BD, et al. Examining patterns of multimorbidity, polypharmacy and risk of adverse drug reactions in chronic obstructive pulmonary disease: a cross-sectional UK Biobank study. BMJ Open. 2018;8(1):e018404.
[18] Corlateanu A, Covantev S, Scutaru E, et al. COPD and comorbidities in the Republic of Moldova. Eurasian Journal of Pulmonology. 2022;24(1):9.
[19] Arinc S, Agca M, Yaman F. Evaluation of nutritional status in COPD according to the GOLD-2015 staging system: a prospective observational study. Eur J Clin Nutr. 2020;74(9):1354-1361.
[20] Sun L, Chen Y, Wu R, Lu M, Yao W. Changes in definition lead to changes in the clinical characteristics across COPD categories according to GOLD 2017: a national crosssectional survey in China. Int J Chron Obstruct Pulmon Dis. 2017;12:3095-3102.
[21] Franssen FM, O’Donnell DE, Goossens GH, Blaak EE, Schols AM. Obesity and the lung: 5. Obesity and COPD. Thorax. 2008;63(12):1110-1117.
[22] Cavailles A, Brinchault-Rabin G, Dixmier A, et al. Comorbidities of COPD. Eur Respir Rev. 2013;22(130):454- 475.
[23] Garcia Rodriguez LA, Wallander MA, Tolosa LB, Johansson S. Chronic obstructive pulmonary disease in UK primary care: incidence and risk factors. COPD. 2009;6(5):369-379.
[24] Dursunoglu N, Kokturk N, Baha A, et al. Comorbidities and their impact on chronic obstructive pulmonary disease. Tuberk Toraks. 2016;64(4):289-298.
[25] Gordon SB, Bruce NG, Grigg J, et al. Respiratory risks from household air pollution in low and middle income countries. Lancet Respir Med. 2014;2(10):823-860.
[26] Ramirez-Venegas A, Torres-Duque CA, Guzman-Bouilloud NE, Gonzalez-Garcia M, Sansores RH. SMALLa AIRWAY DISEASE IN COPD ASSOCIATED TO BIOMASS EXPOSURE. Rev Invest Clin. 2019;71(1):70-78.
[27] Eisner MD, Anthonisen N, Coultas D, et al. An official American Thoracic Society public policy statement: Novel risk factors and the global burden of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2010;182(5):693-718.
[28] Camp PG, Ramirez-Venegas A, Sansores RH, et al. COPD phenotypes in biomass smoke- versus tobacco smokeexposed Mexican women. Eur Respir J. 2014;43(3):725- 734.
[29] Kaya O. QUALITY OF LIFE AND BODE INDEX ACCORDING TO DIFFERENT GOLD STAGES IN COPD PATIENTS [Medical Speciality Thesis]: Chest Diseases Department, Pamukkale University 2014.

APA	Sertçelik Ü, Sertçelik A, Huseynova K, Alkan A, Damadoglu E, Coplu L (2023). The Association Between Comorbidities and a High-Risk Status According to COPD GOLD Groups. , 27 - 34. 10.32552/2022.ActaMedica.818
Chicago	Sertçelik Ümran,Sertçelik Ahmet,Huseynova Khurshud,Alkan Asli,Damadoglu Ebru,Coplu Lutfi The Association Between Comorbidities and a High-Risk Status According to COPD GOLD Groups. (2023): 27 - 34. 10.32552/2022.ActaMedica.818
MLA	Sertçelik Ümran,Sertçelik Ahmet,Huseynova Khurshud,Alkan Asli,Damadoglu Ebru,Coplu Lutfi The Association Between Comorbidities and a High-Risk Status According to COPD GOLD Groups. , 2023, ss.27 - 34. 10.32552/2022.ActaMedica.818
AMA	Sertçelik Ü,Sertçelik A,Huseynova K,Alkan A,Damadoglu E,Coplu L The Association Between Comorbidities and a High-Risk Status According to COPD GOLD Groups. . 2023; 27 - 34. 10.32552/2022.ActaMedica.818
Vancouver	Sertçelik Ü,Sertçelik A,Huseynova K,Alkan A,Damadoglu E,Coplu L The Association Between Comorbidities and a High-Risk Status According to COPD GOLD Groups. . 2023; 27 - 34. 10.32552/2022.ActaMedica.818
IEEE	Sertçelik Ü,Sertçelik A,Huseynova K,Alkan A,Damadoglu E,Coplu L "The Association Between Comorbidities and a High-Risk Status According to COPD GOLD Groups." , ss.27 - 34, 2023. 10.32552/2022.ActaMedica.818
ISNAD	Sertçelik, Ümran vd. "The Association Between Comorbidities and a High-Risk Status According to COPD GOLD Groups". (2023), 27-34. https://doi.org/10.32552/2022.ActaMedica.818

APA	Sertçelik Ü, Sertçelik A, Huseynova K, Alkan A, Damadoglu E, Coplu L (2023). The Association Between Comorbidities and a High-Risk Status According to COPD GOLD Groups. Acta Medica, 54(1), 27 - 34. 10.32552/2022.ActaMedica.818
Chicago	Sertçelik Ümran,Sertçelik Ahmet,Huseynova Khurshud,Alkan Asli,Damadoglu Ebru,Coplu Lutfi The Association Between Comorbidities and a High-Risk Status According to COPD GOLD Groups. Acta Medica 54, no.1 (2023): 27 - 34. 10.32552/2022.ActaMedica.818
MLA	Sertçelik Ümran,Sertçelik Ahmet,Huseynova Khurshud,Alkan Asli,Damadoglu Ebru,Coplu Lutfi The Association Between Comorbidities and a High-Risk Status According to COPD GOLD Groups. Acta Medica, vol.54, no.1, 2023, ss.27 - 34. 10.32552/2022.ActaMedica.818
AMA	Sertçelik Ü,Sertçelik A,Huseynova K,Alkan A,Damadoglu E,Coplu L The Association Between Comorbidities and a High-Risk Status According to COPD GOLD Groups. Acta Medica. 2023; 54(1): 27 - 34. 10.32552/2022.ActaMedica.818
Vancouver	Sertçelik Ü,Sertçelik A,Huseynova K,Alkan A,Damadoglu E,Coplu L The Association Between Comorbidities and a High-Risk Status According to COPD GOLD Groups. Acta Medica. 2023; 54(1): 27 - 34. 10.32552/2022.ActaMedica.818
IEEE	Sertçelik Ü,Sertçelik A,Huseynova K,Alkan A,Damadoglu E,Coplu L "The Association Between Comorbidities and a High-Risk Status According to COPD GOLD Groups." Acta Medica, 54, ss.27 - 34, 2023. 10.32552/2022.ActaMedica.818
ISNAD	Sertçelik, Ümran vd. "The Association Between Comorbidities and a High-Risk Status According to COPD GOLD Groups". Acta Medica 54/1 (2023), 27-34. https://doi.org/10.32552/2022.ActaMedica.818